Figure s1. IPSS and Qmax after treatment (RCT only).

Study or Subgroup Mean SD Total Mean SD Total Meight V, Fixed, 95% Cl	A. IPSS		TPV			TURP			Std. Mean Difference	Std Moa	n Difference		B. Qmax		BTPV		,	TURP			Std. Mean Difference	Std. Mean Di	fforonco
1.1.1 1-month Nulnopiu 2011 8.9 3.7 43 8.4 2.3 47 38.1% 0.16 [-0.25, 0.58] 2011 Geavitee 2015 6.2 8.75 7.1 3 71 61.9% -0.17 [-0.50, 0.15] 2015 Geavitee 2015 6.2 8.75 7.1 3 71 61.9% -0.07 [-0.50, 0.15] 2015 Helterogeneity: Chi* = 1.55, d=1 (P=0.21); P= 35% Test for overall effect: Z=2.0.34 (P=0.21); P= 35% Test for overall effect: Z=2.88 (P=0.004) 1.1.2 3-month Nulnopiu 2011 5.9 2.9 43 5.7 2.1 47 34.4% 0.08 [-0.33, 0.49] 2011 Nulnopiu 2011 5.9 2.9 43 5.7 2.3 71 55.7% -0.18 [-0.50, 0.15] 2015 Geavitee 2015 5.3 2.2 75 5.7 2.3 71 55.7% -0.18 [-0.50, 0.15] 2015 Elisaka 2016 1.5 2.1 8.4 7.8 1.8 49 .9% Not estimable 2015 Geavitee 2015 2.1 8.3 8.7 5.23 2.3 5.9 100 Not estimable Nulnopiu 2011 1.7 6.1 43 18.2 6.3 47 29.9% -0.08 [-0.35, 0.48] 2016 Nulnopiu 2011 1.7.7 6.1 43 18.2 6.3 47 29.9% -0.08 [-0.35, 0.48] 2017 Not estimable 2017 Subtoal (95% C) Helterogeneity: Chi* = 1.0.0001; P= 98% Test for overall effect: Z=2.86 (P=0.0001): P= 98% Test for overall effect: Z=2.56 (P=0.001) 1.1.4 >= 1.2 month Nulnopiu 2011 1.7 6.1 43 18.2 6.3 47 29.9% -0.08 [-0.45, 0.23] Nulnopiu 2011 1.7 6.1 43 18.2 6.3 47 29.9% -0.08 [-0.45, 0.23] Helterogeneity: Chi* = 1.0.0001; P= 98% Test for overall effect: Z=2.86 (P=0.0001): P= 98% Test for overall effect: Z=2.56 (P=0.0001): P= 98% Test for overall effect: Z=2.56 (P=0.00001): P= 98% Test for overall effect: Z=0.000001: P= 98% Test for overall effect: Z=0.00001: P=0.00001: P=0.0	Study or Subgroup			Total				Weir				•	Study or Subgroup			Total			Total				
Subspice 2015									,,,,	,	T									g	11) 1 11104, 0070 01	11,111,00,	
Seawlete 2015 6.6 2.8 75 7.1 3 71 61 9% -0.17 (0.50 0.15) 2015 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 118 100.0% -0.38 (0.63 0.021) 18 18 18 100.0% -0.38 (0.63 0.021) 18 18 18 18 100.0% -0.38 (0.63 0.021) 18 18 18 18 100.0% -0.38 (0.63 0.021) 18 18 18 18 18 100.0% -0.38 (0.63 0.021) 18 18 18 18 18 18 18		8.9	3.7	43	8.4	1 2.3	47	38.	1% 0.16 [-0.25, 0.58] 2011		-			21.4	3.8	75	23.2	3.6	71	61.3%	-0.48 [-0.81, -0.15]	-	
Subtotal (95% C)										4	<u>.</u>											-	
Test for overall effect: Z = 0.34 (P = 0.73) Test for overall effect: Z = 0.86 (P = 0.004) 1.1.2 3-month Aboutable 2015											•								118			♦	
Test for overall effect: Z = 0.34 (P = 0.73) Test for overall effect: Z = 2.86 (P = 0.004) 1.1.2 3-month Aboutable 2015	Heterogeneity: Chi ² =	1.55. df =	= 1 (P =	= 0.21)): 2 = 3	35%							Heterogeneity: Chi ² =	1.04. df	= 1 (P	= 0.31); 2 = 49	%					
Numboglu 2011 5.9 2.9 4.3 5.7 2.1 47 34.4% 0.08 [-0.33, 0.49] 2011 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 6.9 6 100 Not estimable 2015 7.7 8 52 2.2 3.5 1.9 100 Not estimable 2017 2.55 2.8 39 5.49 7.2 1 47 42 Not estimable 2017 2.55 2.8 39 5.49 7.2 1 47 49 Not estimable 2017 2.55 2.8 39 5.49 7.2 1 47 49 Not estimable 2017 2.55 2.8 39 5.49 7.2 1 47 49 Not estimable 2017 2.55 2.8 39 5.49 7.2 1 4.0 2.99% 0.05 [-0.79, -0.33] Heterogeneity: Chi² = 10.1.9, di² = 2 (P < 0.00001); i² = 98% Test for overall effect: Z = 2.68 (P = 0.0007) 1.1.3 6-month 2.1.3 6-month 2.1.3 6-month 2.1.4 9 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 2.1.3 6-month 2.1.4 9 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 2.1.4 9 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 2.1.4 9 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 2.1.4 9 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 2.1.4 2 1.2 month 2.1.4 ≥ 12-month 2.1.4 ≥ 12-mo	Test for overall effect:	Z = 0.34	(P = 0	.73)									Test for overall effect:	Z = 2.86	6 (P = 0	0.004)							
Aboutaleb 2015 7, 7 8 52 6.9 6 100 Not estimable 2015 Geavitet 2015 5.3 2.2 75 5.7 2.3 71 55.7% -0.18 [-0.50, 0.15] 2015 Elsakka 2016 15.2 1.8 40 7.8 1.8 42 9.9% 4.07 [3.30, 4.04] 2016 Kranzbühler 2017 25.6 2.88 39 5.49 3.4 4.9 9.9% 4.07 [3.30, 4.04] 2016 Kranzbühler 2017 25.6 2.88 39 5.49 3.4 4.9 9.9% 4.07 [3.30, 4.04] 2016 Kranzbühler 2017 25.6 2.88 8 [-0.00001]; P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.56 (P = 0.01) 1.1.4 >= 12-month Nuncipul 2011 6.4 3.3 43 6.2 3.1 47 38.1% 0.06 [-0.15, 0.38] 2015 Test for overall effect: Z = 2.68 (P = 0.0001); P = 98% Test for overall effect: Z = 2.68 (P = 0.0001); P = 98% Test for overall effect: Z = 2.68 (P = 0.0001); P = 98% Test for overall effect: Z = 2.68 (P = 0.0001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.68 (P = 0.00001); P = 98% Test for overall effect: Z = 2.47 (P = 0.01) 11.4.4 >= 12-month Geavlete 2015 1.4.4 2.6 14 2.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Geavlete 2015 4.5 1.4 75 4.4 1.9 71 61.9% 0.06 [-0.26, 0.38] 2015 Subtotal (98% CI) 1.8 18 18 10.00% 0.06 [-0.19, 0.32] Helterogeneity: Chi' = 30.01, d.14 2.6 14 2.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Helterogeneity: Chi' = 3.00.00001; P = 9.0000001; P = 9.000000000000000000	1.1.2 3-month												1.2.2 3-month										
Seawlete 2015 5.3 2.2 75 5.7 2.3 71 55.7% -0.16 [-0.50, 0.15] 2015 Seawlete 2015 5.3 2.2 75 5.7 2.3 71 55.7% -0.16 [-0.50, 0.15] 2015 Subtotal (95% CI) 9.5 4.3 4.49 Not estimable veletrogeneity: Chi** = 94.2, df = 2 (₱ = 0.0091); F = 98% Test for overall effect: Z = 2.68 (₱ = 0.007) 1.1.3 6-month Subtotal (95% CI) 130 7.1 1.9 42 [-0.35, 0.22] 2015 Subtotal (95% CI) 130 7.1 1.9 42 [-0.35, 0.23] 2016 Subtotal (95% CI) 130 7.1 1.9 42 [-0.35, 0.23] 2016 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 6.3 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 71 72.5 3.1 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% CI) 158 71 72.5 3.1 1.8 1.5 12.2 3.1 1.5 12.2 3	Nuhoglu 2011	5.9	2.9	43	5.7	7 2.1	47	34.4	l% 0.08 [-0.33, 0.49] 2011		+		Aboutaleb 2015	25	1.2	52	23.5	1.9	100		Not estimable		
Elsakas 2016 15.2 1.8 40 7.8 1.8 42 9.9% 4.07 [3.30, 4.84] 2016 Kranzbühler 2017 2.52 3.1.08 39 2.079 1.47 49 Not estimable (Kranzbühler 2018 2.58 3.1.08 39 2.079 1.47 49 Not estimable (Kranzbühler 2018 2.58 3.1.08 39 2.079 1.47 49 Not estimable (Kranzbühler 2.58 4.86 (P < 0.00001): P = 9.9% Test for overall effect: Z = 2.88 (P = 0.001) 1.1.43 6-month Nuhgelu 2011	Aboutaleb 2015	7.7	8	52	6.9	9 6	100						Elsakka 2016	16.6	2.2	40	18.8	2	42	23.9%	-1.04 [-1.50, -0.58]		
Nuncylip 2017 2.56 2.58 39 5.49 3.4 49 Not estimable 2017 Nuncylip 2011 17.7 6.1 43 18.2 6.3 47 29.9% -0.08 [0.49, 0.33] Subtotal (95% CI) 158	Geavlete 2015	5.3	2.2	75	5.7	2.3	71	55.7	7% -0.18 [-0.50, 0.15] 2015	+	*		Geavlete 2015	21.9	3.4	75	24.1	3.6	71	46.2%	-0.63 [-0.96, -0.29]	-	
Subtotal (95% C)	Elsakka 2016	15.2	1.8	40	7.8	3 1.8	42	9.9	9% 4.07 [3.30, 4.84] 2016				Kranzbühler 2017	23.23	1.08	39	20.79	1.47	49		Not estimable		
Heterogeneity: Chi² = 101.09, df = 2 (P < 0.00001); P² = 98% Test for overall effect: Z = 2.68 (P = 0.007) 1.1.3 6-month 2.5 deavlete 2015	Kranzbühler 2017	2.56	2.58		5.49	3.4					1.		Nuhoglu 2011	17.7	6.1		18.2	6.3				· •	
Test for overall effect: Z = 2.68 (P = 0.007) Test for overall effect: Z = 4.86 (P < 0.00001) 1.1.3 6-month 1.2.3 6-month 1.2.3 6-month Elsakka 2016 16.7 1.5 40 19.5 1.6 42 25.7% -1.79 [-2.30, -1.27] Geaviete 2015 4.9 1.9 75 5.1 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Slaskka 2016 12.2 1 40 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 Slaskka 2016 12.2 1 40 7.1 1.9 42 16.3% 3.0 [2.63, 3.98] 2016 Subtotal (95% CI) 130 128 100.0% 0.36 [0.08, 0.63] Heterogeneity: Chi² = 9.0.15, df = 2 (P < 0.00001); P = 98% Test for overall effect: Z = 2.486 (P < 0.00001) 1.2.3 6-month Elsakka 2016 16.7 1.5 40 19.5 1.6 42 25.7% -1.79 [-2.30, -1.27] Geaviete 2015 22.3 3.5 75 24.4 3.6 71 62.1% -0.59 [-0.92, -0.26] Subtotal (95% CI) 130 128 100.0% -0.73 [-0.99, -0.46] Heterogeneity: Chi² = 3.0.15, df = 2 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.45 (P < 0.00001); P = 94% Test for overall effect: Z = 5.47 (P = 0.01)	Subtotal (95% CI)			158			160	100.0	0.33 [0.09, 0.57]		♦		Subtotal (95% CI)			158			160	100.0%	-0.56 [-0.79, -0.33]	♦	
1.1.3 6-month 2.7 ang 2012	Heterogeneity: Chi2 =	101.09, d	df = 2 (I	P < 0.0	00001)	; 2 = 9	98%						Heterogeneity: Chi2 =	9.42, df	= 2 (P	= 0.009	9); I ² = 7	79%					
Elsakka 2016 16.7 1.5 40 19.5 1.6 42 25.7% -1.79 [2.30, -1.27] Seavlete 2015 4.9 1.9 75 5.1 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Subtotal (95% Cl) 130 128 100.0% 0.36 [0.8, 0.63] Heterogeneity: Chi² = 90.15, df = 2 (P < 0.00001); i² = 98% Test for overall effect: Z = 0.47 (P = 0.64) Elsakka 2016 16.7 1.5 40 19.5 1.6 42 25.7% -1.79 [2.30, -1.27] Geavlete 2015 22.3 3.5 75 24.4 3.6 71 62.1% -0.59 [-0.92, -0.26] Subtotal (95% Cl) 130 128 100.0% 0.36 [0.8, 0.63] Heterogeneity: Chi² = 90.15, df = 2 (P < 0.00001); i² = 98% Test for overall effect: Z = 0.47 (P = 0.64) Elsakka 2016 16.7 1.5 40 19.5 1.6 42 25.7% -1.79 [2.30, -1.27] Geavlete 2015 22.3 3.5 75 24.4 3.6 71 62.1% -0.59 [-0.92, -0.26] Subtotal (95% Cl) 130 128 100.0% -0.73 [-0.99, -0.46] Heterogeneity: Chi² = 33.01, df = 2 (P < 0.00001); i² = 98% Test for overall effect: Z = 5.45 (P < 0.00001) 1.1.4 >= 12-month Geavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Geavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Geavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -0.06 [-0.48, 0.35] Subtotal (95% Cl) 18 18 18 100.0% 0.06 [-0.26, 0.38] 2015 Subtotal (95% Cl) 18 17 5 6.9 43 17.9 5.9 47 81.8% -0.06 [-0.48, 0.35] Subtotal (95% Cl) 57 69 100.0% -0.47 [-0.85, -0.10] Heterogeneity: Chi² = 20.78, df = 1 (P < 0.00001); i² = 95% Test for overall effect: Z = 2.47 (P = 0.01)	Test for overall effect:	Z = 2.68	(P = 0	.007)									Test for overall effect:	: Z = 4.86	6 (P < 0	0.0000	1)						
Geavlete 2015 4.9 1.9 75 5.1 1.8 71 70.4% -0.11 [-0.43, 0.22] 2015 Elsakka 2016 12.2 1 40 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 Subtotal (95% Ct) 130 -0.00001); ² = 98% Test for overall effect: Z = 2.56 (P = 0.01) 1.1.4 >= 12-month Nuhoglu 2011 6.4 3.3 43 6.2 3.1 47 38.1% 0.06 [-0.35, 0.48] 2011 Geavlete 2015 4.5 1.4 75 4.4 1.9 71 61.9% 0.06 [-0.26, 0.38] 2015 Subtotal (95% Ct) 118 118 100.0% 0.06 [-0.48, 0.35] Subtotal (95% Ct) 118 118 118 100.0% 0.06 [-0.48, 0.35] Heterogeneity: Chi ² = 20.78, df = 1 (P = 0.99); ² = 9% Test for overall effect: Z = 2.47 (P = 0.01) Heterogeneity: Chi ² = 2.0.74 (P = 0.64)	1.1.3 6-month												1.2.3 6-month										
Elsakka 2016 12.2 1 40 7.1 1.9 42 16.3% 3.30 [2.63, 3.98] 2016 Subtotal [95% Cl)	Zhang 2012	4.2	8	15	9.3	3.7	15	13.3	3% -0.80 [-1.54, -0.05] 2012		-		Elsakka 2016	16.7	1.5	40	19.5	1.6	42	25.7%	-1.79 [-2.30, -1.27]		
Subtotal (95% CI) 130 128 100.0% 0.36 [0.08, 0.63]	Geavlete 2015	4.9	1.9	75	5.1	1.8	71	70.4	l% -0.11 [-0.43, 0.22] 2015		#		Geavlete 2015	22.3	3.5	75	24.4	3.6	71	62.1%	-0.59 [-0.92, -0.26]	=	
Heterogeneity: Chi² = 90.15, df = 2 (P < 0.00001); l² = 98% Test for overall effect: Z = 2.56 (P = 0.01) 1.1.4 >= 12-month Nuhoglu 2011 6.4 3.3 43 6.2 3.1 47 38.1% 0.06 [-0.35, 0.48] 2011 Seavlete 2015 4.5 1.4 75 4.4 1.9 71 61.9% 0.06 [-0.26, 0.38] 2015 Subtotal (95% Cl) 118 118 100.0% 0.06 [-0.19, 0.32] Heterogeneity: Chi² = 30.01, df = 2 (P < 0.00001); l² = 94% Test for overall effect: Z = 5.45 (P < 0.00001) 1.2.4 >= 12-month Geavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Nuhoglu 2011 17.5 6.9 43 17.9 5.9 47 81.8% -0.06 [-0.48, 0.35] Subtotal (95% Cl) 118 118 100.0% 0.06 [-0.19, 0.32] Heterogeneity: Chi² = 2.0.78, df = 1 (P < 0.00001); l² = 95% Test for overall effect: Z = 2.47 (P = 0.01)		12.2	1		7.1	1.9					1.			16.3	5.7		12.5	3.1					-
Test for overall effect: Z = 2.56 (P = 0.01) Test for overall effect: Z = 5.45 (P < 0.00001) 1.4 >= 12-month Auhoglu 2011 6.4 3.3 43 6.2 3.1 47 38.1% 0.06 [-0.35, 0.48] 2011 Seavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Nuhoglu 2011 17.5 6.9 43 17.9 5.9 47 81.8% -0.06 [-0.48, 0.35] Subtotal (95% Cl) 118 118 100.0% 0.06 [-0.19, 0.32] Heterogeneity: Chi² = 0.00, df = 1 (P = 0.99); i² = 0% est for overall effect: Z = 0.47 (P = 0.64) Test for overall effect: Z = 5.45 (P < 0.00001) 1.2.4 >= 12-month Geavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Nuhoglu 2011 17.5 6.9 43 17.9 5.9 47 81.8% -0.06 [-0.48, 0.35] Subtotal (95% Cl) 57 69 100.0% -0.47 [-0.85, -0.10] Heterogeneity: Chi² = 20.78, df = 1 (P < 0.00001); i² = 95% Test for overall effect: Z = 2.47 (P = 0.01)	Subtotal (95% CI)			130			128	100.0	0.36 [0.08, 0.63]		•		Subtotal (95% CI)			130			128	100.0%	-0.73 [-0.99, -0.46]	♦	
1.1.4 >= 12-month Nuhogiu 2011 6.4 3.3 43 6.2 3.1 47 38.1% 0.06 [-0.35, 0.48] 2011 Geavlete 2015 4.5 1.4 75 4.4 1.9 71 61.9% 0.06 [-0.26, 0.38] 2015 Subtotal (95% CI) 118 118 100.0% 0.06 [-0.19, 0.32] Heterogeneity: Chi² = 0.00, df = 1 (P = 0.99); i² = 0% Test for overall effect: Z = 0.47 (P = 0.64) 1.2.4 >= 12-month Geavlete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Nuhogiu 2011 17.5 6.9 43 17.9 5.9 47 81.8% -0.06 [-0.48, 0.35] Subtotal (95% CI) 5 14 10 10 10 10 10 10 10 10 10 10 10 10 10	Heterogeneity: Chi2 = 5	90.15, df	= 2 (P	< 0.00	0001);	$I^2 = 98$	3%						Heterogeneity: Chi ² =	33.01, c	df = 2 (F	o.00	0001); l ²	2 = 94%	•				
Suhoglu 2011 6.4 3.3 43 6.2 3.1 47 38.1% 0.06 [-0.35, 0.48] 2011 Seavilete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Seavilete 2015 14.4 2.6 14 21.8 3.4 22 18.2% -2.32 [-3.20, -1.44] Nuhoglu 2011 17.5 6.9 43 17.9 5.9 47 81.8% -0.06 [-0.48, 0.35] Subtotal (95% CI) 57 69 100.0% -0.47 [-0.85, -0.10] Heterogeneity: Chi² = 20.78, df = 1 (P < 0.00001); i² = 95% Test for overall effect: Z = 2.47 (P = 0.01)	Test for overall effect:	Z = 2.56	(P = 0	.01)									Test for overall effect:	Z = 5.4	5 (P < 0	0.0000	1)						
Seaviete 2015 4.5 1.4 75 4.4 1.9 71 61.9% 0.06 [-0.26, 0.36] 2015 Subtotal (95% CI) 118 118 100.0% 0.06 [-0.19, 0.32] Heterogeneity: Chi² = 0.00, df = 1 (P = 0.99); l² = 0% Test for overall effect: Z = 0.47 (P = 0.64) Test for overall effect: Z = 0.47 (P = 0.04)	.1.4 >= 12-month												1.2.4 >= 12-month										
Subtotal (95% CI) 118 118 100.0% 0.06 [-0.19, 0.32]	Nuhoglu 2011	6.4	3.3	43	6.2	2 3.1	47	38.1	1% 0.06 [-0.35, 0.48] 2011		*		Geavlete 2015	14.4	2.6	14	21.8	3.4	22	18.2%	-2.32 [-3.20, -1.44]		
Heterogeneity: Chi² = 0.00, df = 1 (P < 0.00001); i² = 95% Test for overall effect: Z = 0.47 (P = 0.64) Heterogeneity: Chi² = 20.78, df = 1 (P < 0.00001); i² = 95% Test for overall effect: Z = 2.47 (P = 0.01)	Geavlete 2015	4.5	1.4		4.4	1.9					*		Nuhoglu 2011	17.5	6.9	43	17.9	5.9			-0.06 [-0.48, 0.35]		
Test for overall effect: Z = 0.47 (P = 0.64) Test for overall effect: Z = 2.47 (P = 0.01) -4 -2 0 2 4 -4 -2 0 2 4	Subtotal (95% CI)			118			118	100.0	0.06 [-0.19, 0.32]		♦		Subtotal (95% CI)			57			69	100.0%	-0.47 [-0.85, -0.10]	•	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Heterogeneity: Chi2 = 0	0.00, df =	= 1 (P =	0.99)); I ² = 0)%							Heterogeneity: Chi2 =	20.78, d	df = 1 (F	o.00	0001); I²	2 = 95%	•				
	Test for overall effect:	Z = 0.47	(P = 0.	.64)									Test for overall effect	Z = 2.4	7 (P = 0	0.01)							
																,							
										1 2	<u>+</u>										_	+ + +	
Favours [TURP] Favours [BPTV] Favours [TURP] Favour											Favoure IR	4 RDT\/I											avoure [RI

Figure 2. PVR and QoL after treatment (RCT only).




Figure 3. Overall, Clavien III-IV and specific complications (RCT only).




Figure 4. Other intraoperative and postoperative parameters (RCT only).

Substitution Subs
Falahatkar 2014
Zhang 2012 39 15.5 15 69.3 24.9 15 4.9% -1.42 [-2.23, -0.61] Elsakka 2016 48.6 5 40 51.2 11.2 4 17.0% -0.29 [-0.73, 0.14] Aboutaleb 2015 53 21 52 62 16 100 Nuhoglu 2011 57.2 13.2 43 53.4 11.7 47 18.6% 0.30 [-0.11, 0.72] Yip 2011 46.2 20.2 46 39.2 17.5 40 17.6% 0.37 [-0.06, 0.79] Geaviete 2015 118.1 27.7 80 99.5 32.6 80 32.0% 0.61 [0.29, 0.93] Subtotal (95% CI) 263 273 100.0% -0.05 [-0.23, 0.12] Heterogeneity: Chi² = 107.49, df = 5 (P < 0.00001): P² = 95% Test for overall effect: Z = 0.60 (P = 0.55) 22.2 Hemoglobin decrease Falahatkar 2014 0.53 0.29 39 1.39 0.45 49 14.8% -2.20 [-2.74, -1.66] Geaviete 2015 0.9 0.6 80 1.7 0.8 40 23.8% -0.56 [-0.98, -0.14] Yip 2011 0.3 0.7 46 0.5 0.8 40 23.4% -0.26 [-0.69, 0.16] Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Not estimable Nuhoglu 2011 0.7 0.3 43 0.9 0.4 47 23.8% -0.56 [-0.98, -0.14] Test for overall effect: Z = 9.01 (P < 0.00001); P² = 91% Test for overall effect: Z = 9.01 (P < 0.00001); P² = 91% Test for overall effect: Z = 9.01 (P < 0.00001); P² = 91% Test for overall effect: Z = 9.01 (P < 0.00001); P² = 91% Test for overall effect: Z = 9.01 (P < 0.00001); P² = 91% Test for overall effect: Z = 9.01 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P = 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 91% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 84% Test for overall effect: Z = 0.00 (P < 0.00001); P² = 84% Test for overall effect: Z = 0.00 (P < 0.00001); P²
Elsakka 2016
Elsakka 2016
Nuhoglu 2011 57.2 13.2 43 53.4 11.7 47 18.6% 0.30 [-0.11, 0.72] Yip 2011 46.2 20.2 46 39.2 17.5 40 17.6% 0.37 [-0.06, 0.79] Geavlete 2015 11.81 27.7 80 99.5 32.6 80 32.0% 0.61 [0.29, 0.93] Subtotal (95% CI) 263 273 100.0% -0.05 [-0.23, 0.12] Heterogeneity: Chi² = 107.49, df = 5 (P < 0.00001); I² = 95% Test for overall effect: Z = 0.06 (P = 0.55) 2.2.2 Hemoglobin decrease Falahatkar 2014 0.53 0.29 39 1.39 0.45 49 14.8% -2.20 [-2.74, -1.66] Geavlete 2015 0.9 0.6 80 1.7 0.8 80 38.0% -1.13 [-1.46, -0.79] Nuhoglu 2011 0.7 0.3 43 0.9 0.4 47 23.8% -0.56 [-0.98, -0.14] Yip 2011 0.3 0.7 46 0.5 0.8 40 23.4% -0.26 [-0.69, 0.16] Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Not estimable Subtotal (95% CI) 208 216 100.0% Not estimable Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); I² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) 2.2.4 Catheterization time (days) Elsakka 2016 1.54 0.17 40 2.01 0.28 42 12.1% -2.00 [-2.53, -1.46] Falahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, 1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jahang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jean 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jean 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jean 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jean 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jean 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Jean 2012 4.1 4.1 1.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 273 100.0% Jean 2012 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1
Nuhoglu 2011
Yip 2011
Geavlete 2015 118.1 27.7 80 99.5 32.6 80 32.0% 0.61 [0.29, 0.93] Subtotal (95% CI)
Subtotal (95% Cl) 263 273 100.0% -0.05 [-0.23, 0.12] Heterogeneity: Chi² = 107.49, df = 5 (P < 0.00001); l² = 95% Test for overall effect: Z = 0.60 (P = 0.55) 2.2.2 Hemoglobin decrease Falahatkar 2014 0.53 0.29 39 1.39 0.45 49 14.8% -2.20 [-2.74, -1.66] Geavlete 2015 0.9 0.6 80 1.7 0.8 80 38.0% -1.13 [-1.46, -0.79] Nuhoglu 2011 0.7 0.3 43 0.9 0.4 47 23.8% -0.56 [-0.98, -0.14] Yip 2011 0.3 0.7 46 0.5 0.8 40 23.4% -0.26 [-0.69, 0.16] Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Not estimable Subtotal (95% Cl) 208 216 100.0% -0.95 [-1.15, -0.74] Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); l² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) 2.2.4 Catheterization time (days) Elsakka 2016 1.54 0.17 40 2.01 0.28 42 12.1% -2.00 [-2.53, -1.46] Falahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] The subtotal (1.54 0.17 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% Cl) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84%
Test for overall effect: Z = 0.60 (P = 0.55) 2.2.2 Hemoglobin decrease Falahatkar 2014
2.2.2 Hemoglobin decrease Falahatkar 2014
Falahatkar 2014 0.53 0.29 39 1.39 0.45 49 14.8% -2.20 [-2.74, -1.66] Geavlete 2015 0.9 0.6 80 1.7 0.8 80 38.0% -1.13 [-1.46, -0.79] Nuhoglu 2011 0.7 0.3 43 0.9 0.4 47 23.8% -0.56 [-0.98, -0.14] Yip 2011 0.3 0.7 46 0.5 0.8 40 23.4% -0.26 [-0.98, 0.16] Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Subtotal (95% Cl) 208 216 100.0% -0.95 [-1.15, -0.74] Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); I² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) Palahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% Cl) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.00001): I² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Falahatkar 2014 0.53 0.29 39 1.39 0.45 49 14.8% -2.20 [-2.74, -1.66] Geavlete 2015 0.9 0.6 80 1.7 0.8 80 38.0% -1.13 [-1.46, -0.79] Nuhoglu 2011 0.7 0.3 43 0.9 0.4 47 23.8% -0.56 [-0.98, -0.14] Yip 2011 0.3 0.7 46 0.5 0.8 40 23.4% -0.26 [-0.98, 0.16] Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Subtotal (95% Cl) 208 216 100.0% -0.95 [-1.15, -0.74] Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); I² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) Palahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% Cl) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.00001): I² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Geavlete 2015
Nuhoglu 2011 0.7 0.3 43 0.9 0.4 47 23.8% -0.56 [-0.98, -0.14] Yip 2011 0.3 0.7 46 0.5 0.8 40 23.4% -0.26 [-0.69, 0.16] Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Not estimable Subtotal (95% CI) Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); l² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) 2.2.4 Catheterization time (days) Elsakka 2016 1.54 0.17 40 2.01 0.28 42 12.1% -2.00 [-2.53, -1.46] Falahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Thing 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001); l² = 84% Test for overall effect:
Yip 2011
Aboutaleb 2015 0.8 0.4 52 1.9 0.8 100 Not estimable 2016 100.0% -0.95 [-1.15, -0.74] Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); I² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) 2.2.4 Catheterization time (days) Elsakka 2016 1.54 0.17 40 2.01 0.28 42 12.1% -2.00 [-2.53, -1.46] Falahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001): I² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Subtotal (95% CI) 208 216 100.0% -0.95 [-1.15, -0.74]
Heterogeneity: Chi² = 35.21, df = 3 (P < 0.00001); l² = 91% Test for overall effect: Z = 9.01 (P < 0.00001) 2.2.4 Catheterization time (days) Elsakka 2016
Test for overall effect: Z = 9.01 (P < 0.00001) 2.2.4 Catheterization time (days) Elsakka 2016
2.2.4 Catheterization time (days) Elsakka 2016
Elsakka 2016 1.54 0.17 40 2.01 0.28 42 12.1% -2.00 [-2.53, -1.46] Fallahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Fig. 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Fig. 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Fig. 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Not estimable Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Fig. 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Falahatkar 2014 4.12 0.33 39 4.77 0.42 49 14.3% -1.68 [-2.17, -1.19] Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001): i² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Nuhoglu 2011 2.26 0.49 43 3.05 0.56 47 15.7% -1.48 [-1.95, -1.01] Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Tip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) -263 -263 -273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); ² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Geavlete 2015 1.3 0.6 80 2.2 1.3 80 32.7% -0.88 [-1.21, -0.56] Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Yip 2011 1.43 0.65 46 1.86 1.02 40 18.6% -0.51 [-0.94, -0.08] Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Zhang 2012 4.1 4.1 15 6.8 6.8 15 6.5% -0.47 [-1.19, 0.26] Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Aboutaleb 2015 2 0.28 52 3 3.2 100 Not estimable Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); I² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Subtotal (95% CI) 263 273 100.0% -1.13 [-1.32, -0.94] Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); I² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Heterogeneity: Chi² = 30.63, df = 5 (P < 0.0001); l² = 84% Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Test for overall effect: Z = 11.91 (P < 0.00001) 2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
2.2.5 Hospitalization time (days) Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Zhang 2012 8.7 1 15 11.7 1.5 15 5.2% -2.29 [-3.24, -1.34]
Geavlete 2015 2.1 0.4 80 3.2 1.5 80 43.2% -1.00 [-1.33, -0.67]
Falahatkar 2014 1.89 0.38 39 2.1 0.51 49 25.7% -0.46 [-0.88, -0.03]
Yip 2011 2.38 1.4 46 2.75 2.06 40 25.9% -0.21 [-0.64, 0.21]
Aboutaleb 2015 1 2.1 52 3 3.3 100 Not estimable
Subtotal (95% CI) 180 184 100.0% -0.72 [-0.94, -0.51] ♦
Heterogeneity: Chi² = 20.25, df = 3 (P = 0.0002); l² = 85%
Test for overall effect: Z = 6.54 (P < 0.00001)
-4 -2 0 2 4
Favours [BPTV] Favours [TURP]